Fulton A - Search Results

1

Microtentacle Formation in Ovarian Carcinoma.

Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Reader JC, et al. Among authors: fulton a. Cancers (Basel). 2022 Feb 4;14(3):800. doi: 10.3390/cancers14030800. Cancers (Basel). 2022. PMID: 35159067 Free PMC article.

2

EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment.

Reader J, Harper AK, Legesse T, Staats PN, Goloubeva O, Rao GG, Fulton A, Roque DM. Reader J, et al. Among authors: fulton a. Cancers (Basel). 2019 Oct 18;11(10):1590. doi: 10.3390/cancers11101590. Cancers (Basel). 2019. PMID: 31635323 Free PMC article.

3

Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Reader J, Holt D, Fulton A. Reader J, et al. Among authors: fulton a. Cancer Metastasis Rev. 2011 Dec;30(3-4):449-63. doi: 10.1007/s10555-011-9303-2. Cancer Metastasis Rev. 2011. PMID: 22002714 Free PMC article. Review.

4

The Role of Eicosanoids in Gynecological Malignancies.

Smith PG, Roque D, Ching MM, Fulton A, Rao G, Reader JC. Smith PG, et al. Among authors: fulton a. Front Pharmacol. 2020 Aug 26;11:1233. doi: 10.3389/fphar.2020.01233. eCollection 2020. Front Pharmacol. 2020. PMID: 32982722 Free PMC article. Review.

5

Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis.

Li Y, Reader JC, Ma X, Kundu N, Kochel T, Fulton AM. Li Y, et al. Breast Cancer Res Treat. 2015 Jan;149(2):403-15. doi: 10.1007/s10549-014-3229-7. Epub 2014 Dec 24. Breast Cancer Res Treat. 2015. PMID: 25537642 Free PMC article.

6

Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.

Kochel TJ, Reader JC, Ma X, Kundu N, Fulton AM. Kochel TJ, et al. Oncotarget. 2017 Jan 24;8(4):6540-6554. doi: 10.18632/oncotarget.14145. Oncotarget. 2017. PMID: 28029661 Free PMC article.

7

Eicosanoids in Cancer: Prostaglandin E₂ Receptor 4 in Cancer Therapeutics and Immunotherapy.

Ching MM, Reader J, Fulton AM. Ching MM, et al. Front Pharmacol. 2020 May 29;11:819. doi: 10.3389/fphar.2020.00819. eCollection 2020. Front Pharmacol. 2020. PMID: 32547404 Free PMC article. Review.

8

Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.

Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, Fulton A. Kundu N, et al. Among authors: fulton a. Breast Cancer Res Treat. 2014 Jan;143(1):19-31. doi: 10.1007/s10549-013-2779-4. Epub 2013 Nov 27. Breast Cancer Res Treat. 2014. PMID: 24281828 Free PMC article.

9

A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE₂-mediated immunosuppression and inhibits breast cancer metastasis.

Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. Ma X, et al. Oncoimmunology. 2013 Jan 1;2(1):e22647. doi: 10.4161/onci.22647. Oncoimmunology. 2013. PMID: 23482441 Free PMC article.

10

Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.

Ma X, Kundu N, Ioffe OB, Goloubeva O, Konger R, Baquet C, Gimotty P, Reader J, Fulton AM. Ma X, et al. Mol Cancer Res. 2010 Oct;8(10):1310-8. doi: 10.1158/1541-7786.MCR-10-0003. Epub 2010 Sep 21. Mol Cancer Res. 2010. PMID: 20858737 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

574 results

Search Page